Mike Serrano-Wu joined the Broad Institute in 2012, and is the Director of Medicinal Chemistry for the Therapeutics Projects Group. His team aspires to transform the process of drug discovery and the treatment of human disease by developing and applying novel drug discovery technologies; targeting novel classes of protein targets, generally viewed as “undruggable”; targeting novel mechanisms emerging from studies of human biology; and working in an open, collaborative environment to establish proof of concept.
Serrano-Wu brings fifteen years of drug discovery and development experience to the Broad. Previously at Bristol-Myers Squibb, he was part of an industry-leading group that discovered the first-in-class HCV NS5A inhibitor daclatasvir, now in late-stage clinical testing and showing promise for highly effective interferon-free therapy. Later at the Novartis Institutes for Biomedical Research, Serrano-Wu co-led a team that identified the first-in-class DGAT1 inhibitor pradigastat, currently in late-stage clinical testing, followed by a second-generation compound that also achieved successful human proof of concept. Serrano-Wu also led a group tasked with drug discovery “beyond MW 500,” which included the investigation of chemically-modified biotherapeutics.
Serrano-Wu received his A.B. and Ph.D. in chemistry from Harvard University.Last updated date: May 2013